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ABSTRACT 
 
BACKGROUND 
 
        Cervical cancer is the fourth most common cancer affecting women worldwide. Pap 
smear screening and histopathological interpretation of cervical biopsy has significantly 
reduced the number of deaths due to cervical cancer. However, they provide little or no 
information regarding the association of HPV in precancerous lesion and invasive 
cervical cancer. Hence the need to use biomarker to know the association of HPV in 
those lesions in order to predict the risk of progression or regression and prognosis. 
P16INKa is a surrogate marker of HPV which fulfils all the above criteria. 
OBJECTIVES 
1. To evaluate the results of expression of p16INK4A in preneoplastic and neoplastic 
lesions of cervix in order to assess the association of HPV infection in those 
lesions. 
 
2. To study the pattern of expression of p16 in various histological types of cervical 
squamous cell lesions by p16 immunohistochemistry. 
 
3. To compare p16 expression in various histological types of cervical squamous cell 
lesions. 
 
 
 
 MATERIALS AND METHODS 
                 Immunohistochemical analysis of p16expression was performed on 60 paraffin 
embedded tissue samples, obtained from cervical biopsy including 25CIN I, 5CIN II, 
4CIN III and 26 SCC. Two parameters were evaluated in p16 expression: Percentage 
ofp16 positive cells and reaction intensity of p16 immunostaining. The p16 expression 
was graded as Negative, Grade 1, 2, 3 and its reaction intensity was graded as Negative , 
Weak, Moderate, Strong. 
RESULTS  
       In the present study out of 60 cases, the incidence of squamous cell carcinoma 
constituted majority (44%).Among CIN group , CIN I constituted majority of the 
preneoplstic lesions of cervix.p16 expression was seen in 28% of CIN I, 80% of CIN II, 
all  CIN III  and  all  SCC cases.  Only  one  CIN I  case  show showed  grade3  staining  and  
strong reaction intensity, but most of the CIN II(60%), CIN III(100%) and SCC(96.15%) 
cases showed grade 3 staining. In our study there was a statistically significant correlation 
between p16 expression, reaction intensity and lesion severity. 
 
 
 
 
CONCLUSION 
       In the present study out of 60 cases, 68.33% of cases showed p16 positivity. In 
preneoplastic lesions, totally 44.12% of cases showed p16 positivity. In invasive 
squamous cell carcinoma cases, 100% cases showed p16 positivity. So p16 may be useful 
as an adjunct in histological sections to know the association of HPV in preneoplastic 
lesions lesions to predict the risk of progression of the disease and to plan proper 
treatment and in neoplastic lesions to predict the prognosis, since HPV negative SCC 
showed poor prognosis in literatures.  
   In our study p16 expression was  correlated well with increasing grade of CIN. So 
p16 has significant implication in diagnostic, prognostic and preventive aspects of 
cervical cancer. 
KEY WORDS 
P16INK4A, Cervical intraepithelial neoplasia, Immunohistochemistry, Human 
papilloma virus. 
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INTRODUCTION 
Cervical cancer is the fourth most common cancer and seventh overall 
among women worldwide, with an estimated incidence of 5,28,000 cases  and 
2,66,000 deaths in 2012 and it is most frequent among women between 15 and 
44 years of age.1Screening by pap smear has reduced the incidence of cervical 
cancer in developed countries, but implementation of this screening technique 
has not been successful in developing countries. Developing countries carry 
major burden of cervical cancer cases (85%) and deaths (88%) worldwide. 
The incidence of this  disease in India is around 1,23,000  cases and  death 
around 67,000 cases every year.2 So cervical cancer is considered as a public 
health problem and World Health Organization(WHO) gives priority to 
cervical cancer control programmes.  
Before the development of invasive squamous cell carcinoma of cervix, 
there are certain stages of premalignant changes that occur in the cervical 
epithelium which are described previously as dysplasia. They are now divided 
into cervical intraepithelial neoplasia (CIN) I, II and III. Bethesda system 
classifies these abnormalities into low grade squamous intraepithelial lesion 
(LSIL) and High grade squamous intraepithelial lesion (HSIL) based on the 
morphology. The LSIL encompasses condyloma and CIN I, whereas HSIL 
encompasses CINII and CIN III. All LSIL cases will not directly progress into 
invasive squamous cell carcinoma. Most cases of LSIL regress spontaneously. 
But all HSIL cases are considered to be at high risk for progression to cervical 
cancer. 
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It is well known that the main causative factor for both precancerous 
and invasive cervical cancer is persistent infection with one or more oncogenic 
types of Human papilloma virus(HPV).3In addition to the infection with  HPV, 
there are several cofactors have been associated with the increased risk of 
persistent infection of high-risk HPVs and  progression to preneoplastic and 
neoplastic lesions of cervix, including Viral infections like HIV, Herpes 
simplex virus–2 (HSV-2)4, Smoking5, Dietary deficiencies6, 
Immunosupression7, Hormonal contraceptives, family history and sexually 
associated factors like multiple sexual partners, Early sexual activity, Sexually 
transmitted diseases, Multiple pregnancies. 
Experimental studies have identified nearly 200 types of Human 
papilloma viruses, of those more than 40 have been identified in the genital 
tract.8 These are divided into those with low risk and high risk categories 
based on the association with invasive cervical carcinoma.HPV16, 18, 31, 33 
and 45 are examples of high-risk types, while HPV6 and 11 belong to the low-
risk types. In a large epidemiological study conducted  in India showed that  
genotypes 16 and 18  either alone or  together  were detected in 76.3% of 
cervical cancer cases  followed by genotype 33.9 
 The two viral oncoproteins in HPV namely E6 and E7 are mainly 
responsible for the progression of neoplasm. The E6 oncoprotein of high risk 
HPV causes degradation of p53, a tumor suppressor gene thus preventing cell 
cycle arrest or apoptosis. Similarly HPV E7 oncoprotein  bind and inactivates 
the tumor suppressor protein pRB ( Retinoblastoma protein), which normally 
inhibits the progression of cell cycle into S phase. 
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P16INK4a (henceforth referred to as p16) is a tumor suppressor protein 
that inhibits cyclin dependant kinase 4 and 6, which phosphorylate the RB 
protein. A reciprocal relation between p16 and pRB expression has been seen, 
suggesting the presence of negative feedback loop allowing pRB to limit the 
concentration of p16. So functional inactivation of pRB by the HPV E7 
oncoprotein results in over expression of p16. 
p16 protein is detectable immunohistochemically, over expression of it 
may serve as a surrogate biomarker of HPV infection which makes it useful in 
evaluating HPV- associated preneoplastic and neoplastic lesions of cervix. 
Many literatures have given evidence that p16 may be a very useful 
marker for preneoplastic, neoplastic squamous lesions and glandular dysplasia 
of cervix. Moreover, expression of p16 appears to correlate with degree of 
cervical neoplasia.10 
Many countries have started vaccination against HPV 16 and 18 and 
mainly targeted towards adolescent girls. Current vaccines provide excellent 
efficacy not only against HPV16and 18, but also provide cross protection 
against non vaccinated types. However HPV vaccines do not protect against 
all invasive forms of cervical cancer.11, 12  In developing countries like India, it 
is necessary to vaccinate all adolescent girls especially in HPV high 
prevalence area. 
Although Pap smear screening test is the easily available test used 
widely, the gold standard for diagnosis of cervical neoplasm is 
histopathological examination of cervical biopsy. When we use p16 IHC as an 
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adjunct to morphological examination, we can recognize the high risk type of 
HPV infection in those lesions which may progress to high grade lesion. 
p16 Immnostaining is a new and cost effective and easily available 
method which gives valuable information regarding the HPV infection without 
the need for molecular techniques such as Polymerase chain reaction( PCR ), 
Southern blotting, or Insitu hybridisation ( ISH ). 
Although there are several previous reports on the role of p16 in 
cervical cancer, there is paucity of them in Indian literature in spite of the fact 
that cervical cancer is one of the most common cancers among females in 
India. 
This study is an attempt to analyze the association of HPV infection   in 
and around Chengalpattu by using p16 immunostaining in preneoplastic and 
neoplastic squamous cell lesions of cervix and evaluate its etiological and 
prognostic benefits as a valuable marker for cervical neoplasm. 
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AIM AND OBJECTIVES 
1. To evaluate the results of expression of p16 in preneoplastic and neoplastic 
lesions of cervix in order to assess the association of HPV infection in 
those lesions. 
2. To study the pattern of expression of p16 in various histological types of 
cervical squamous cell lesions by p16 immunohistochemistry. 
3. To compare p16 expression in various histological types of cervical 
squamous cell lesions. 
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REVIEW OF LITERATURE 
Epidemiology  
Cervical cancer has become a serious public health issue, being the 
fourth most common cancer in women worldwide .1There is a drastic 
difference in incidence rate and prevalence of cervical cancer between 
developed and developing countries. Many developed countries have become 
successful in reducing the cancer burden over the past six decades through 
screening programme and other diagnostic workup. Because of the lack of 
proper health facilities, cervical cancer is leading in developing countries like 
India. 
The age-standardized incidence and mortality rate of cervical cancer in 
India are 27.0 and 15.2, respectively.13 An estimated incidence of 1,23,000 
cases and 67,000  deaths due to cervical cancer occurred in India in 2012, 
contributing 23.2% and 25.2% to the global cervical cancer incidence and 
mortality respectively.14It has been estimated that there will be around 205496 
new cases and 119097 deaths due to cervical carcinoma by 2020 in India, 
contributing to 29% and 30% respectively of the global burden of cervical 
cancer cases and mortality.15Cytological screening by pap smear  is a very 
useful test but false positive (15 – 50%) and false negative rates (30%) are 
high. So histopathological examination of cervical biopsies is regarded as a 
confirmatory examination in the assessment of cervical neoplasm.5 
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Embryology of Cervix:- 
Female reproductive tract organs including uterus, cervix, uterine tubes, 
and upper part of vagina are developed from mullarian duct, otherwise called 
as paramesonephric ducts, are a pair of ducts which are present in the 
intermediate mesoderm. They are formed by invagination of coelomic 
epithelium. The paramesonephric duct consists of upper vertical part, middle 
horizontal part and lower vertical part. The upper vertical part lies lateral to 
the Wolffian duct. Middle horizontal part crosses in front of the Wolffian duct. 
Both upper and middle part forms the fallopian tube. Lower vertical part fuses 
with the similar part of the opposite side to form uterovaginal canal in which 
upper part forms the body of the uterus and cervix, while the lower part forms 
the upper 4/5 th of vagina. The mullarian ducts meets the endoderm derived 
urogenital sinus at mullarian tubercle which meet a pair of endodermal 
sinovaginal bulbs which forms the lower 1/5 th of the vagina.16 
 
Figure 1: Development of Cervix 
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Gross Anatomy:-    
 The uterus is divided into body of the uterus (corpus uteri) which forms 
the upper two-third, and the cervix (cervix uteri) which forms the lower third. 
In the adult nulliparous state the cervix tilts forwards relative to the axis of the 
vagina, called as ante version, and the body of the uterus tilts forward relative 
to the cervix called as ante flexion. The cervix measures 2.5 cm in length in 
the adult nulligravida. The lower part of the cervix projects into vagina which 
divides it into supravaginal and vaginal parts. The parametrium separates the 
supravaginal portion of the cervix anteriorly from the bladder and also passes 
laterally between the anterior and posterior layers of the broad ligaments. The 
vaginal part of the cervix projects into the anterior vaginal wall. The spaces 
between this part and the vaginal wall are called the vaginal fornices. Through 
the internal os the upper end of the cervix communicates with the uterus and 
through external os the lower end of the cervix opens into the vagina. The   
vaginal portion of the cervix is called as ectocervix and the portion related to 
the endo cervical canal is known as endo cervix. In nulliparous women, the 
external os is small and circular, whereas after childbirth become a transverse 
slit. The cavity of the cervix is fusiform in shape.17, 18, 19 
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Figure 2:  Anatomy of cervix showing angles of antevertion and ante 
flexion 
VASCULAR SUPPLY OF THE CERVIX 
Arterial supply 
The descending branches of the uterine arteries, reaches the lateral wall 
of the cervix along the upper margin of the paracervical ligaments and 
supplies the cervix 
Venous drainage 
The veins from the cervix form a cervical plexus and run along the 
lateral border of the uterus. The cervical plexus drains through the uterine, 
ovarian and vaginal veins into internal iliac veins. 
 10 
 
LYMPHATIC DRAINAGE 
Lymphatics from the cervix pass laterally in the parametrium and drain 
into four efferent channels running toward the external iliac and obturator 
nodes, the hypo gastric and common iliac nodes, the sacral nodes, and the 
nodes of the posterior wall of the urinary bladder. 
 
Figure 3:Vascular supply and the lymphatic drainage of the cervix.20 
NERVE SUPPLY  
The cervix is supplied by nerves from the pelvic autonomic system, the 
superior, middle and inferior hypo gastric plexuses. Pain sensation from the 
cervix passes along the parasympathetic nerves. The nerve supply is mainly 
restricted to the endocervix and peripheral deep portion of ectocervix. This 
causes relative insensitivity of the vaginal portion of the cervix to pain. 
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LIGAMENTS OF CERVIX  
The paracervical ligaments, otherwise called as mackenrodt’s ligament 
and the uterosacral ligaments, attach the supra vaginal portion of the cervix to 
the second vertebrae through fourth sacral vertebrae, are the greatest sources 
of fixation and support of the cervix. 
HISTOLOGY OF CERVIX  
The cervix has a covering epithelium and an underlying stroma. The 
stroma is an admixture of fibrous, muscular, and elastic tissue. Most of the 
ectocervix is covered by non keratinizing stratified squamous epithelium, and 
is composed of three layers of squamous cells: Basal/ parabasal, intermediate, 
superficial cells. The basal cell layer is one cell thick, with scant cytoplasm 
and oval nuclei oriented perpendicularly to the basement membrane. The 
nuclear cytoplasmic ratio decreases progressively from the basal to superficial 
cells during normal maturation. The parabasal cells are larger than basal cells 
and have more cytoplasm. The cells in the midzone are called as intermediate 
cells. The superficial cells have abundant cytoplasm and a  pyknotic nuclei 
than the intermediate cells, and they orient with their longest axis parallel to 
the basement membrane. The morphological appearance of this various layers 
varies with age. The cells are become atrophic and exhibit high nuclear 
cytoplasmic ratio during post menopausal period. 
The Endocervix and the endocervical glands are lined by mucinous 
columnar epithelium. The endocervical glands, represents infoldings of the 
surface epithelium rather than true glands.21 
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The junction between squamous and mucinous epithelia is known as 
squamocolumnar junction (SCJ) 22.At birth, SCJ is located on the endocervix 
which is called as original squamocolumnar junction. Under the influence of 
estrogen at puberty and pregnancy, the endocervix everts to expose the 
columnar epithelium, glycogenisation of the epithelium takes place, 
lactobacilli colonize the epithelium and the PH becomes acidic. These changes 
stimulate the columnar epithelium to undergo metaplasia and convert into 
immature squamous and later mature squamous epithelium. With these 
changes the histologic squamocolumnar junction moves to the external os and 
this is called as functional or new columnar junction. The area between the 
original SCJ and the new SCJ is the transformation zone where columnar 
epithelium is slowly replaced by active metaplasia and this the area where 
most cervical preneoplastic and neoplastic lesions develop.23 
 
Figure 4 : Schematic diagram of transformation zone.24 
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Figure 5 : Transformation zone of uterine cervix.25 
ETIOLOGY AND PATHOGENESIS 
Human papilloma virus  
It is now well accepted that cervical cancer is caused by Human 
papilloma virus. Almost all cervical cancer are directly associated with 
infectivity with one or more of the oncogenic types of HPV. Approximately 
7.9% of women in the general population are estimated to harbor cervical 
HPV infection at a given time. About 82.5% of invasive cervical cancers are 
attributed to HPV16 or HPV18. All cervical squamous cell cancers as well as 
distinct subsets of vulvar, vagina, anal and oral cancers among women and 
penile anal and oral cancers among men are causally associated with HPV 
infection. 
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Epidemiology and Natural history of Human papilloma virus infection 
            Papilloma viruses are classified as members of papovaviridae family. 
These are circular double-stranded DNA viruses with approximately 8000 
base pairs in length and measures 45 – 55nm in diameter. Its icosahedral 
capsid composed of 72 capsomers.26Papilloma viruses are epitheliotrophic 
viruses, means it predominantly infect skin and mucous membrane.27 
Many lines of evidence have demonstrated that the association between 
HPV and many types of cervical diseases ranging from the innocuous 
condyloma acuminatum to fatal invasive squamous cell carcinoma.28,29,30  At  
present about 200 types of HPV have been identified and it  can be further 
divided into high- and low-risk types depending on their carcinogenic 
potential.31,32,33. 
A large epidemiologic study by Munoz et al observed  data from nine 
countries has identified15 high risk HPV types (16, 18, 31, 33, 35, 39, 45, 51, 
52, 56, 58, 59, 68, 73, 82),three probably high risk types(26,53,66) and low  
risk types (6, 11, 40, 42, 43, 44, 54, 61, 70, 72, 81 and cp6108).34Of the HPV 
types infecting the anogenital mucosa, 12 types have been classified as group 
1 carcinogens to humans and one is probably of carcinogenic (Group 2A) 
type. All these 13 HPV types, and also several other possibly carcinogenic 
types (Group 2B), belong to the same evolutionary branch of the alpha genus 
in the phylogenetic tree of papillomaviruses (Figure 6). 35, 36, 37 
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Figure6 : Phylogenetic tree of Alpha – Human papilloma virus.HPV types 
in red clade are associated with CIN 3 and cervical cancer.HPV types in 
blue clade cause genital warts. HPV in green clade cause commensal 
infections.38 
 
International Agency for Research Cancer (IARC) classified thirteen 
anogenital HPV as oncogenic, based on their association with cervical and 
anogenital  cancer which are HPV16,18,31,33,35,39,45,51,52,56,58,59 and 
66.39In a study by Bosch et al, it was concluded that majority of HPV 
infections are transient and clear within few months. Persistent high risk HPV 
infection of the cervical epithelium triggers neoplastic proliferation.40, 41 
A meta analysis of HPV types in women with LSIL found that HPV was 
detected in 80% of the LSIL from North America and approximately 70% of 
LSIL from other regions of the world.42 
Multiple types of HPV are frequently found in association with LSIL. 
 16 
 
TABLE 1: Types of Human papilloma virus with oncogenic risk. 43 
Low oncogenic risk 6, 11, 42, 43, 44, 53 
High oncogenic risk 16, 18,  31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 
Unclear oncogenic risk 26, 68, 73, 82 
 
A number of studies have demonstrated that prevalence of HPV 16 
from different regions of the world range from 30% to 70%.42, 44 HPV 16, 18 
and 31 have been mostly associated with invasive cervical cancer.31,45A large 
epidemiological study conducted by L loveras et al , evaluate the distribution 
of HPV types in invasive cervical cancer and  showed HPV types 16,18,31,33 
and 45 strains cause 85% of the invasive cervical carcinoma worldwide.46 
Genomic organization of Human papilloma virus 
 HPV – DNA consist of distinct three different regions. They are early 
region (ER), late region (LR), upstream regulatory region (URR).The Early 
region is composed of seven genes,E1 – E7,which play a significant role in 
viral replication and have oncogenic properties. Late region is composed of 
two genes, namely L1, the major capsid protein, which can self assemble into 
virus like particles which are used for the generation of the currently available 
VLP based HPV vaccines, and L2, the minor capsid protein that is thought to 
facilitate encapsidation of viral DNA and viral infectivity, The URR is the 
regulatory region which contains binding sites for both viral and cellular 
transcription factors.  
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Figure 7 :  Genomic organisation of HPV.47 
In preneoplastic lesions of cervix the HPV DNA is not integrated into 
the host DNA, rather it is found in circular or episomal form. The episomal 
HPV produces mostly the E2 protein. This E2 protein encodes for a DNA 
binding protein that binds to a specific nucleotide motif found in E6 and E7 
region. 48,49 E2 regulates the expression of E6 and E7.So that only minimal 
amount of E6 and E7 is produced. When the episomal form integrates into the 
host chromosome at E1/E2 region, causing break in this region, results in 
uncontrolled production and expression of E6 and E7 proteins. This E6 protein 
forms a complex with p53 tumor suppressor protein leading to degradation of 
p53.50The viral E7 oncoprotein binds to the Retinoblastoma protein (pRb),a 
tumor suppressor protein and inactivates it. Inactivation of pRb mediates 
release of transcription factor E2F,which activates the genes necessary for 
entry of cell into S phase. The accumulation of E2F has been associated with 
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an increase in INK4A gene transcription, the INK4A gene product, the p16 
INK4A protein (p16).  
P16, a tumor suppressor gene, located on chromosome 9p21, is belongs 
to the inhibitors of cyclin dependant kinase (CDK) 4 family. p16INK4ais named 
after its molecular weight (15,845) and its role in inhibiting CDK4.Normally 
CDK4 and CDK6 binds cyclin D and forms an active protein complex  ,which 
phosphorylate retinoblastoma protein(pRb) .The phosphorylation  of pRb 
induces release of transcription factor E2F from its bound state allowing it to 
enter into the nucleus. Once in the nucleus E2F promotes the transcription of 
target genes that are essential for cell cycle progression. p16 binds to the 
CDK4 and CDK6 and preventing its interaction with cyclin D. This interaction 
ultimately inhibits the downstream activities of transcription factors, such as 
E2F and arrest G1-S transition. So inactivation of pRB by E7 causes over 
expression of p16, because p16 is regulated by negative feedback of pRB.51 
p16 expression is not associated with proliferation, but it is associated with 
senescence and cell cycle arrest. So p16 expression is not seen in normal cells 
and actively proliferating cells. 
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Figure 8 :  Molecular basis for cervical neoplasia . This figure shows 
three pathways involved in HPV related tumorigenesis including  
alteration in the cell cycle activity induced by E7, up regulation of 
telomerase via E6 with loss of replicative senescence, and induction of 
centrosome instability by E6 and E7  with HPV 16 as a model. 
Progression is also associated with promoter methylation of tumor 
suppressor gene.52 
 
In a recent study by Iana Leniskova et al concluded that, p16  
expression was not seen in normal cervical tissue, but its expression was 
increased in following  frequency : CIN 1 (180/249; 72.3%),CIN2 (212/233; 
91.0%). CIN3 (178/181; 98.5%) and invasive carcinoma (131/133; 98.5%). 
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Life Cycle of Human papilloma virus 
HPV initially infects the basal cells or immature squamous cells. It 
enters into the basal cell layer through defects in the epithelium and remains 
within the cell in two distinct biological states. In one form HPV continues to 
remains in the basal cells, without producing virions, this is referred as latent 
infection. In other form viral DNA replication occurs independently of host 
chromosomal DNA synthesis, results in large amount of viral DNA formation. 
Viral DNA replication mainly occurs in intermediate and superficial squamous 
cells which show the distinct cytological and morphological abnormality, 
including acanthosis, koilocytosis, multinucleation and nuclear pleomorphism. 
 
Figure9: Human papilloma virus life cycle 53 
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Figure10: Koilocytic changes in the cervical squamous epithelium.54 
HPV E7 protein is entrapped inside the nucleus. So it is not exposed to 
the antigen presenting cell, moreover it inhibits the function of interferon Į 
and ȕ. HPV viral proteins which are recognized by dentritic cell are carried to 
the lymph nodes and also presented to the T cells. The CD4 and CD8 T cells 
are activated and reach the infected site to destroy the virus. But the Human 
papilloma virus expose only few viral particles to immune surveillance 
mechanism, therefore it resides for many years without clinical recognition 
Other Risk Factors 
Infection with high risk HPV virus is necessary factor for the 
development of cervical cancer, it is not sufficient for the development of 
cervical cancer. Because only a small proportion of women exposed to HPV 
develop cervical cancer, suggest that additional cofactors are necessary in the 
pathogenesis of cervical neoplasia. These factors may modify the risk in 
women infected with HPV 
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Smoking 
Szarewski et al concluded that there is a positive association between 
cigarette smoking and the development of cervical cancer. Some of the studies 
demonstrated that smoking may be a risk factor only for squamous cell 
carcinoma, not for adenocarcinoma of cervix.55, 56 
Oral Contraceptives 
A Meta analysis of 28 studies concluded that the relative risk of 
invasive cervical cancer increased with increasing duration of contraceptive 
use. There is no associated risk for intraepithelial lesion if it is used less than 5 
years but the risk increases to 3 times and 4 times higher if they use oral 
contraceptives for 5 – 9 yrs and more than 10 years respectively. A large 
reanalysis of epidemiological studies conducted in more than 50,000 women 
has confirmed that oral contraceptive use increases the risk of cervical 
cancer.57, 58. 
Infections other than HPV 
Sexually transmitted infections, especially Chlamydial infection is 
found to be one of a risk factor. Viral infections like Human 
immunodeficiency virus (HIV) ,Herpes simplex virus -2also plays an 
important role in the development of cervical neoplasm. The risk of 
developing cervical cancer is 9.2 times more in women infected with HIV than 
non infected women.59 
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Immunosuppression 
Immunity determines whether the patient is cleared of HPV infection or 
whether it is persist and progress into malignancy. Studies showed a  relative 
risk of 13.6 for the development of cervical carcinoma in situ in renal 
transplant recipients compared to women in the general population.60  Because 
of the immunosupression in HIV status ,they are more prone to develop 
cervical cancer than women in general population. 
Sexually associated factors  
Multiple sexual partners, early age at first intercourse, early marriage, 
male sexual behavior, concurrent penile cancer in males are also an important 
sexually associated factors in pathogenesis of cervical neoplasm. 
Other factors  
There are various other risk factors associated with development of 
cervical cancer. They are dietary deficiency, early age at first pregnancy, 
multiparity, low socioeconomic class. 61, 62 
 
 
 
 
 24 
 
Table2:  Risk factors for cervical cancer: HPV infection vs. persistence 
and Malignant transformation 
Risk factor HPV infection 
HPV persistence 
And transformation 
Multiple sex partners + n.e. 
Partner’s multiple partners + n.e 
Poor hygiene + n.e 
Absence of male 
circumcision + + 
Immunodeficiency, HIV + + 
High parity n.e + 
Oral contraceptives n.e + 
Smoking n.e + 
STDs other than HPV n.e + 
Poor nutritional status n.e + 
 
STDs = Sexually transmitted diseases (especially C, trachomatis). 
n.e = No evidence for being a risk factor at this time. 
Studies in transgenic K14E7 mouse models showed that estrogen 
receptor is required for the initiation and maintenance of cervical cancer .63 
Another study demonstrated that HPV oncogenes promote squamous 
cell carcinoma by an additional mechanism of micro RNAs. 64, 65 
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TABLE 3:WHO Histological classification of tumors of the uterine cervix 
I EPITHELIAL TUMORS :- 
1. Squamous Tumours and precursors 
1A 
Squamous cell carcinoma, not 
otherwise specified 
¾ Keratinizing 
¾ Non -Keratinizing 
¾ Basaloid 
¾ Verrucous 
¾ Warty 
¾ Papillary 
¾ Lymphoepithelioma – like  
¾ Squamotransitional 
1B. Early Invasive squamous Cell Carcinoma  
1C. 
Squamous intraepithelial neoplasia  
 
¾ Cervical intraepithelial 
 neoplasia 
¾ Squamous Cell Carcinoma 
 insitu 
1D. Benign Squamous Cell lesions 
¾ Condyloma  acuminatum  
¾ Squamous Papilloma 
¾ Fibro Epithelial polyp 
II Glandular tumours and precursors 
III Other epithelial tumours  
IV Mesenchymal tumours and tumour like conditions 
V Mixed epithelial and mesenchymal tumours 
VI Melanocytic tumours 
VII Miscellaneous tumours 
VIII Lymphoid and haematopoietic tumours 
IX Secondary tumours 
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PRENEOPLASTIC LESIONS OF CERVIX 
Natural history of cervical intraepithelial neoplasia 
 Genital HPV lesions are more common among women in reproductive 
age group, but most of them are asymptomatic. On average 50% of the 
infections cleared within 8 months and 90% of the HPV infections cleared 
within two years. Persistent high risk HPV type infection is the major risk 
factor for the development of both squamous cell carcinoma and 
adenocarcinoma of the cervix.33However, the natural history of squamous cell 
carcinoma of cervix is well understood than adenocarcinoma.66 The 
development of cervical cancer is a multistep process in which precancerous 
lesions persist, progress and regress overtime except the last step leading to 
invasive lesion is not reversible. 
The precancerous lesions of cervix are usually described as cervical 
intra epithelial neoplasia. 67The cellular changes in precancerous lesions of 
cervix involves nuclear atypia, increased nuclear cytoplasmic ratio, mitotic 
activity limited to the surface epithelium and do not extend beyond the base 
ment membrane. There are different classification systems for cervical 
precursor lesions which are used interchangeably overtime. Older 
Papanicolaou classification used the term as ‘atypical cells with abnormal 
features’. Another classification system grouped the lesions into mild, 
moderate, severe dysplasia and carcinoma in situ. The cellular changes are 
limited to lower one third of epithelium in mild dysplasia, extend to middle 
one third in moderate dysplasia and to upper one- third in severe dysplasia. 
Full thickness involvement is called carcinoma in situ. This was followed by 
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cervical intraepithelial neoplasia (CIN) classification. In this classification 
mild dysplasia were termed CIN I, moderate dysplasia CIN II, and severe 
dysplasia and carcinoma insitu termed CIN III. This three tier classification 
system has been recently simplified into two tier system  , with CIN I , 
condyloma acuminatum, Exophytic condylomas and squamous papilloma are 
coming under  low grade squamous intraepithelial lesion (LSIL) and CIN II 
,CIN III and carcinoma insitu combined into one category called as high grade 
squamous intraepithelial lesion (HSIL).68 
Table4 : Classification of HPV associated intraepithelial lesions of       
cervix.69 
Term HPV risk category 
Comparison of classification systems 
Two-tiered 
CIN Dysplasia/CIS SIL 
Exophytic 
condyloma Low risk _______ _______ LGSIL 
Squamous 
papilloma Low risk _______ _______ LGSIL 
Flat 
condyloma 
Low and 
high risk _______ _______ LGSIL 
CIN 1 Low and high risk 
Low grade 
CIN Mild dysplasia LGSIL 
CIN 2  High risk High grade CIN 
Moderate 
dysplasia HGSIL 
CIN 3 High risk High grade CIN 
Severe 
dysplasia/ CIS HGSIL 
CIN = Cervical intraepithelial neoplasia 
SIL = Squamous intraepithelial lesion 
CIS =  Carcinoma in situ 
LG  = Low grade 
HG = High grade  
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Generally more than 80% of LSIL lesions and 100% of HSIL lesions 
are associated with high risk HPV types. A study conducted by Moscicki et al 
,showed in terms of CIN lesions of any grade, up to 90% regress 
spontaneously in women aged 13 to 22 years , whereas among women 34 
years and older, the estimated risk of regression is only 40%. In Boyes et al 
study, 77% of the most severe preinvasive lesions, carcinoma in situ, regressed 
spontaneously among women younger than 40 years-old whereas the 
estimated rate of regression is 61% among women aged 40 and older. 
McCredie et al undertook study in New Zeeland reported that 20% of women 
with untreated CIN3 lesions developed cancer cervix within 10 years and 31% 
within30years. Generally, the median time from initial exposure to HPV to the 
development of carcinoma in situ is at least 7 to 12 years.70 
Table5:  Natural history of CIN depend upon lesion grade.71 
 % Regression % Persist Progress to CIS 
CIN 1 57 32 11 
CIN 2 43 35 22 
CIN 3 32 56 12 
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Figure 11 : Progression Model of Cervical Carcinoma 
 
Figure 12 :  A classic schematic diagram of cervical intraepithelial 
neoplasia (lower) defines the cytopathologic (A -E) and histopathologic 
(F-J) transitions from normal to LSIL (CIN-I) toHSIL (CIN2 & 3).52 
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Low grade squamous intraepithelial lesion (LSIL) 
Normal squamous cell nuclei become smaller when they mature and 
move towards the surface. In low grade squamous intraepithelial lesion also 
cells are mature squamous cells with polygonal shape, but nuclei are enlarged 
at least 3 – 4 times, that of normal intermediate cell nucleus. The cells become 
smaller and the nuclei become smaller and pyknotic, irregular nuclear contour 
sometimes with bi/multinucleation and cytoplasmic halos when HPV changes 
are evident. These pyknotic nuclei may also exhibit features like increased size 
that of the normal superficial squamous cell and a mild nuclear atypia, fine to 
coarsely granular and evenly distributed chromatin, hyperchromasia. Bi 
nucleated cells are present in 90% of the LSIL and when they surrounded by 
cytoplasmic halo are termed koilocytes.52 
Condyloma acuminatum, Immature condyloma / squamous papilloma, 
Flat condyloma are the three morphological subsets of LSIL. 
Moreover, LSIL do not progress directly to invasive cervical cancer, 
because most cases regress spontaneously, only few cases progress to HSIL. 
So LSIL is not treated like a premalignant condition. 
High grade squamous intra epithelial lesion 
High grade squamous intraepithelial lesion is characterized by presence 
of atypical cells with nuclear pleomorphism, irregular nuclear contours and 
coarse chromatin along with loss of cell polarity, increased mitotic index with 
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mitosis in the upper half of the epithelium and abnormal mitotic figures. If 
these abnormalities involve one third to two third of mucosal thickness, it is 
said to be Cervical intra epithelial lesion 2(CIN2),and more than two- thirds ,it 
is called as cervical intraepithelial lesion 3(CIN3).Apart from the above, 
nuclear cytoplasmic ratio is considered as a important  criterion to diagnosis of 
HSIL. The nuclei in LSIL can be markedly enlarged and pleomorphic but have 
low nuclear cytoplasmic ratio, whereas the nuclei in HSIL are more uniform 
but with irregular nuclear contours and high nuclear cytoplasmic ratio. LSIL 
involves superficial layers of the mucosa, whereas in HSIL the atypical cells 
extend upwards from the basal layer to at least one third of the mucosal 
thickness. 
Early invasive (micro invasive) squamous cell carcinoma 
It is defined as stromal invasion of malignant squamous cells by less 
than or equal to 3mm in depth and 7mm in length. But assessment of this early 
stromal invasion is very difficult. The criteria for the diagnosis of early 
invasion include 
1. Desmoplastic response in the adjacent stroma 
2. conspicuous maturation of malignant squamous epithelium 
3. Blurring of epithelial stromal interface 
4. Loss of polarity of nuclei at the epithelial stromal interface.72 
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Invasive squamous cell carcinoma 
The most common malignant tumor of female genital tract in both 
developed as well as developing countries is invasive squamous cell 
carcinoma of cervix. The role of HPV in the pathogenesis of all squamous cell 
carcinoma has become obvious, which was discovered by Harald zur Hausen, 
for that he was awarded the Noble prize in 2008. 
Invasive squamous cell carcinoma of cervix can be classified by grade ( 
well differentiated, moderately differentiated and poorly differentiated) and/or 
by morphology ( Large cell keratinizing,  Large cell non keratinizing and 
small cell non keratinizing) . WHO now recommend two tiered classification 
as keratinizing and non keratinizing tumors to avoid confusion with small cell 
carcinoma. But the grade and type have not found to be prognostically 
significant, instead, the depth of invasion, size, lymphatic or vascular invasion 
are the important prognostic variables. 
MORPHOLOGY 
Gross 
Grossly, invasive cervical carcinoma may be polypoid or fungating or 
deeply infiltrative. Infiltrative carcinomas invade adjacent structures more 
commonly than polypoidal type. 
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MICROSCOPY 
Keratinizing 
These tumors are considered as well differentiated tumor , shows 
conspicuous evidence of keratinization in the form of keratin pearls, 
keratohyaline granules, individual keratinized cells and nests of squamous cell 
with central keratinization.The nuclei are large, hyper chromatic with coarse 
chromatin. Mitotic figures are not commonly seen. 
Non keratinizing 
These tumors are composed of large squamous cells which are 
polygonal in shape with eosinophilic cytoplasm but lack the evidence of 
keratin pearls. Cellular and nuclear pleomorphism is more obvious with 
numerous mitotic figures. Non keratinizing carcinomas are typically 
moderately differentiated. 
Basaliod 
Some invasive  squamous cell carcinoma have nests of basal type 
squamous cells having scant eosinophilic cytoplasm and peripheral palisading 
of nuclei with variable amount of squamous differentiation. These carcinomas 
are typically poorly differentiated. 
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OTHER RARE VARIANTS OF SQUAMOUS CELL CARCINOMA 
Verrucous 
     These tumors are exophytic and composed of broad based  papillae 
lined by squamous epithelium with little or no atypia. These tumors have 
pushing margin. 
Warty or condylomatous 
     These tumors are exophytic squamous cell carcinoma that have 
koilocytic surface epithelial changes characteristic of HPV infection. 
Papillary 
This type of tumor is characterized by a papillary growth pattern and it 
is subdivided into three histological subtypes. 
1. Papillary undifferentiated carcinoma: - In this carcinoma, the tumor cells 
lining the papillae do not show histological evidence of specific type of 
differentiation. 
2. Papillary transitional cell carcinoma: - Has a similar histologic appearance 
to lesions that occur in the urinary tract. 
3. Papillary squamotransitional carcinoma:-which has a combination of 
transitional and squamous features. 
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Lymphoepithelial – like 
It resembles undifferentiated nasopharyngeal carcinoma and consists of 
poorly defined aggregates of nonkeratinizing tumor cells with large vesicular 
nuclei, prominent nucleoli and moderate amount of eosinophilic cytoplasm, 
syncytial appearance and heavy lymphocytic infiltration.73 
DIAGNOSIS AND AIDS TO DIAGNOSIS   
Diagnosis is done by 
- History 
- Physical  examination  
- Investigations 
History 
Any women of reproductive age presenting with abnormal uterine 
bleeding, post coital bleeding, white discharge, pelvic pain, mass per vaginum, 
urinary or bowel symptoms should suggest the possibility of cervical cancer. 
Physical Examination 
x General examination – Cachexia, pallor , supraclavicular and  inquinal 
nodes 
x Systemic examination  
x Abdominal examination – Ascites, Enlarged uterus, Hepatomegaly 
x Speculum examination – Growth on the cervix (Type of growth, Bleeds 
on touch, Fixity). 
 36 
 
Investigations  
- Pap smear 
- HPV testing 
- Cervical biopsy 
- Cystoscopy / proctoscopy/IVP 
- USG/CT / MRI 
- Complete blood count, liver function test, Renal function test. 74 
PREVENTION AND EARLY DETECTION OF CERVICAL CANCER 
Prevention of cervical cancer  consists of creating awareness about the 
risk factors through health education, promoting practice of safe sex, use of 
condoms to prevent STDs, lifestyle modification, screening and early 
treatment of  premalignant lesions and HPV vaccines. 
Cervical cancer screening 
Several screening methods are available, but cytology (Pap smear) is 
the most widely used method. 
Methods used for cervical cancer screening 
x Cytology 
Conventional cytology ( Pap smear ) 
      Liquid based cytology (LBC) 
Manual interpretation 
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Automated screening 
x Visual inspection after acetic acid(VIA ) 
x Visual inspection after acetic acid with magnification(VIAM ) 
x Visual inspection after Lugol’s iodine(VILI) 
x Cervical biopsy 
x HPV  testing 
x Investigational strategies 
Polar probe 
      Laser – induced fluorescence 
HPV detection techniques 
1. Immunohistochemistry 
2. Southern Blot  
3. Dot Blot assays 
4. In situ Hybridization 
5. Hybrid capture 2 assay (HC2) 
6. Polymerase chain reaction 
7. HPV genotyping 
8. Immunocytochemical detection of L1 capsid protein 
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The only test presently approved by U.S.Food and Drug Administration 
is the Hybrid capture 2 assay (HC2) test..But it is not widely available. Among 
the above mentioned tests , immunohistochemistry, In situ Hybridization,PCR 
are the most commonly used methods.  
CERVICAL CYTOLOGY 
The abnormal cells of cervical neoplastic exfoliate which can be 
collected by scraping the cervix and staining the smear. Based on the severity 
of abnormality, it is possible to diagnose cervical pre-neoplastic and neoplastic 
lesions . This method of screening was first introduced by Papanicolaou and is 
known as Pap test or Pap smear. 
Screening guidelines 
x Begin at age 21 
x Screen every 2 years till age 30 
x Screen every 3 years from age 30 if 
Three consecutive negative smears 
        No CIN II or III / HIV infection in the past 
        Not immunocompromised 
        No DES exposure in utero 
x Stop screening at 65 – 70 if previous three smears negative, except when 
performed for CIN II /III 
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x No screening after hysterectomy 
x Conventional cytology or LBC can be used 
x For women > 30 years ,combined cytology and HPV testing recommended 
Table 6: The Bethesda System of Cytologic Classification (2001)     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Specimen type 
  Indicate conventional smear (Pap smear) versus liquid based versus other  
Specimen adequacy  
x Satisfactory for evaluation 
x Unsatisfactory for evaluation (specify reason)  
x Specimen rejected / not processed (specify reason)  
x Specimen processed and examined, but unsatisfactory for  
      evaluation of epithelial abnormality because of (specify reason) 
 General categorization (optional) 
x Negative for intraepithelial lesion or malignancy  
x Epithelial cell abnormality. (See Interpretation/result [specify 
x 'squamous' or 'glandular' as appropriate)) 
x Other: See Interpretation/result (e.g., endometrial cells in a woman  
over 40 years of age)  
Automated review (specify)  
Ancillary testing (specify) 
 Interpretation/result  
Negative for intraepithelial lesion or malignancy  
x Organisms (specify) 
x Other non-neoplastic findings (optional to report; list not inclusive)  
x Other (specify)  
Epithelial cell abnormalities  
x Squamous cell  
x Atypical squamous cells of undetermined significance (ASCUS)  
cannot exclude HSIL (ASC-H)  
x Low-grade squamous intraepithelial lesion (LSIL) encompassing: HPV/miki 
dysplasia/CIN-1 
x  High-grade squamous intraepithelial lesion (HSIL) encompassing: moderate 
and severe dysplasia, CIS/CIN-2 and CIN-3 (with features suspicious for 
invasion (if invasion is suspected) 
Squamous cell carcinoma 
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MANAGEMENT OF ABNORMAL SMEARS 
The risk of developing CIN II or III after ASC-US is approximately 5- 
10%.So aggressive management is not required. HSIL is found in 25% of 
women with ASC-H, therefore immediate colposcopy is recommended. 
Colposcopy is usually the course of action in LSIL since CIN II or III may be 
found in 15 – 20%.All women with HSIL must have immediate colposcopy 
evaluation. 
COLPOSCOPY 
Colposcopy is performed in all women with abnormal cytology. 
Colposcopy helps in localization of the lesion and taking a directed cervical 
biopsy 
MANAGEMENT OF LSIL 
Since rate of progression of LSIL to invasive cancer is low ,aggressive 
management is not indicated. Repeat smear 6 - 12 months later.HPV DNA 
testing may be performed at 12 months, and if negative, routine screening is 
recommended. 
MANAGEMENT OF HSIL 
HSIL lesions are treated by excision or ablation.76 
Treatment modalities 
¾ Ablative procedures 
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- Thermo ablation 
¾ Cryotherapy 
- Carbondioxide laser 
¾ Excisional procedures 
   -   Loop electroexcision procedures 
   -   Cold knife conisation 
   -  Carbon dioxide laser 
¾ Hysterectomy 
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Table 7:TNM and FIGO Classification of carcinoma of the uterine cervix 
TNM Classification T- Primary Tumour 
TNM 
Categories 
FIGO 
Stages 
 
 
 
Tx 
 
Pnmary tumour cannot be assessed 
To 
 
No evidence of pnmary tumour 
Tis 0 Carcinoma in situ, (preinvasive carcinoma) 
T1 1 Cervical carcinoma confined to uterus (extension to corpus should be disregarded) 
T1a IA 
Invasive carcinoma diagnosed only by microscopy. 
All macroscopically visible lesions even with 
superficial invasion are Tlb/ Stage 1B 
T1a1 IA1 Stromal invasion no greater than 3.0 mm in depth and 7.0 mm or less in horizontal spread 
T1a2 IA2 
Stromal invasion more than 3.00 mm and not more 
than 5.0 mm with a horizontal spread 7.0 mm or 
less 
T1b 1B 
Clinically visible lesion confined to the cervix or 
microscopic lesion greater than Tla2/1A2 
T1b1 1B1 
Chnical visible lesion 4.0 cm or less in greatest 
Dimension. 
T1b2 1B2 
Clinically Visible lesion more than 4 cm in greatest 
Dimension. 
T2 II 
Tumour invades  beyond uterus but not to pelvic 
wall 
or to lower third of the vagina. 
T2a IIA Without parametrial invastion 
T2b IIB With parametrial invasion 
T3 III 
Tumour extends to pelvic wall, involves lower 
third of vagina, or causes hydronephrosis or non-
functioning kidney 
 43 
 
T3a IIIA Tumour involves lower third of Vagina no extension to pelvic wall. 
T3b IIIB Tumour extends to pelvic wall or causes  hydronephrosis or non-functioning kidney 
T4 IVA Tumour invades mucosa of the bladder or rectum or extend beyond true pelvis.  
 
N- Regional Lymph Nodes  
NX  Regional lymphnodes can not be assessed  
N0  No regional lymphnode metastasis 
N1  Regional lymphnode metastasis 
 
M - Distant metastasis 
M1 IVB Distant metastasis 
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TREATMENT OF INVASIVE CERVICAL CARCINOMA 
Treatment of invasive squamous cell carcinoma involves surgery, 
Radiotherapy, Chemotherapy depending on the extent of tumor involvement 
and general condition of the patient. FIGO  stage IA1 tumors can be treated 
with simple hysterectomy or large loop excision in women who wish to 
preserve fertility.77 Patients with FIGO Stage IA2 tumors and above are treated 
with modified radical hysterectomy and regional lymph node dissection. 
Patients with FIGO stage IB to IIA tumors can be treated with radical 
hysterectomy or with radiation therapy.78  FIGO IIB to IVB tumors are treated 
with radiation therapy and concurrent chemotherapy .In case of post 
irradiation relapse of cervical carcinoma, pelvic exentration should be 
considered.79 
x Stage IA1 – Conisation or simple hysterectomy 
x Stage IA2 – Modified radical hysterectomy  with  pelvic 
lymphadenectomy 
x Stage IB1 – Radical hysterectomy with pelvic lymphadenectomy(or) 
chemo radiation 
x Stage IB2 – Radical hysterectomy with pelvic lymphadenectomy and  
postoperative radiation 
x Stage III – Chemo radiation 
x Stage IVA – Chemo radiation 
x Stage IVB – Palliative radiation(or) palliative chemotherapy 
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SPREAD AND METASTASIS 
Direct spread 
 The squamous cell carcinoma of cervix spreads to uterus, vagina, 
parametrium, Utrosacral ligaments and lower urinary tract by direct extension. 
Lymphatic spread 
Lymph node metastasis proceeds in a sequential fashion. The 
paracervical, hypogastric, obturator and external iliac groups are the first 
station, and the second station is represented by the sacral, common iliac, 
aortic and inguinal groups. The nodal involvement is directly related to the 
stage of the disease.80 
Hematogenous spread 
 Distance metastasis may be seen in lungs (9%),bones (4%),liver and 
other structures.81, 82 
Prognosis 
 The prognosis of invasive squamous cell carcinoma of cervix is related 
to the following parameters. 54 
1. Clinical staging :- most important prognostic determinator 
2. Nodal status, size and number of positive nodes 
3. Depth of invasion 
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4. Endometrial extension, parametrial involvement and blood vessel 
invasion 
5. Microscopic type 
6. Microscopic grade 
7. Tumor associated tissue eosiniphilia;-  
This feature is regarded as good prognostic sign. 
8. Cell proliferation index 
9. HPV:- Lombard I, Vincent – Salomon et al  study shows ,patients with 
intermediate risk HPV ,the 5 year disease free survival was 100%, 58% 
for patients with HPV16 positive tumors and 38% for patients with 
HPV18 positive tumors. Also absence of detection of HPV in the tumor 
cells indicate poor prognostic sign. 
10. Expression of HER2/neu, RAS oncogene, Tn antigen, allelic loss of 
chromosome1,stromal infiltration by S-100 protein positive langerhans 
cells are associated with poor prognosis. 
MARKERS  COMMONLY USED IN PRENEOPLASTIC AND 
NEOPLASTIC SQUAMOUS LESIONS OF CERVIX:- 
p16INK4a  :- 
Many literatures have demonstrated that p16INK4a may be a useful 
marker for preneoplastic and neoplastic squamous cell lesions of cervix.p16ink4a 
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is a cellular correlate of the increased expression of the viral oncoprotein E7 
which distrupt the tumor suppressor protein, pRb. The disturbance of the Rb 
pathway leads to a compensatory over expression of p16 through a negative 
feedback loop.83Furthermore , p16 over expression is correlate well with the 
degree of cervical neoplasia.10,84 The role of p16 INK4A  has been reviewed in 
many  previous articles85,86   These  reviews showed significant heterogeneity 
in methods used for defining p16 positivity, so  there is wide range in the 
sensitivity(59% – 96%) and the specificity (41% – 96%) reflecting 
heterogeneity in interpretation and analyzed population. Over expression of 
p16 is seen only when HPV has integrated into the genome of the host and this 
does not occur in low risk types of HPV.p16 is generally a nuclear protein, but 
overproduction of it force it into the cytoplasm. 
Murphy et al in 2005 analyzed and compared the expression patterns of 
three potential biomarkers p16, CDC6 and MCM5.Among three markers they 
found that the p16 as a reliable marker of cervical dysplasia and its expression 
was closely linked with high risk HPV infection. 
In some of the studies, p16 was used as a prognostic marker. A four 
year follow up study conducted by Negri et al in 2004 assessed the role of p16 
in predicting the progression of CIN I to CIN III. They concluded that p16 was 
seen in low grade lesions of cervix which may undergo spontaneous 
regression, but cases with diffuse p16 staining had a significantly higher 
chance to progress to high grade lesion than p16 negative cases.(109) A 2 year 
follow up study by omori et al in 2007 observed that CIN 2 lesions with 
diffuse p16 staining had a higher risk of progression to CIN 3.87 
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MIB – 1 as a proliferation marker in cervical neoplasia :- 
MIB -1 (Molecular immunology Borstel) is an important proliferation 
marker for CIN. Gerdes et al in 1990 demonstrated that MIB -1 antibody 
detects Ki – 67 antigen in the G1,S, G2 and M phase, but it is absent in G0 
phase. Ki – 67 is an antigen expressed in proliferating cells. Several studies 
have demonstrated that this antibody may be a useful marker of proliferative 
activity of preneoplastic and neoplastic lesions of cervix.  
Keating et al in 2001 analyzed the staining patterns of p16 and MIB- 1 
in normal, reactive epithelial changes, LSIL and HSIL. Expression of these 
markers are closely linked to the grade of the SIL .Positive scores for Ki -67 
and p16 were seen in 68.4% and 100% of LSIL and 94.7% and 100% of HSIL 
respectively. 
Markers of aberrant S-phase induction :- 
The cell cycle activation mediated by HPV oncogene in transforming 
infections is characterized by aberrant S – phase induction. Topoisomerase IIA 
(TOP2A) and minichromosome maintenance protein 2 (MCM2) are the two 
proteins detected by an assay which is commercially available ( proEx C ) . 
There are only few literatures that studied these markers and that too on 
minimal samples and their result showed sensitivity  of  67% - 99% and 
specificity of 85%. 88 
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Other biomarkers undergoing clinical validation :- 
Other cellular makers such as CK13 and CK1489, MCM5 and CDC690, 
Survivin91and CEA.92, Telomerase /TERC and Ki – 67 have also been 
evaluated in various stages of development. But most of them are marked by 
non-uniformity in determination of end points and limited sample sizes. Other 
viral markers like  HPV L1 capsid protein93and E6 oncoprotein94detection are 
also under study, but further evidence is needed to confirm  their utility. 
Among all of the immunomarkers, p16 INK4A expression is 
considered as a valuable and cost effective marker for cervical intraepithelial 
neoplasia and squamous cell carcinoma of cervix.95According to different 
studies, immunohistochemistry (IHC) has a sensitivity of 52-87% for the 
detection of HPV.96 
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MATERIALS AND METHODS 
Study place: 
Departement of Pathology, Chengalpattu Medical College, 
Chengalpattu 
Study design: 
 The present cross-sectional study was a prospective study conducted in 
the Department of Pathology during the period of June 2014 to August 2015. 
Ethical clearance for the study was obtained from the Ethics Committee of 
Chengalpattu medical college, Chengalpattu. 
A total sample of 60 cases, including both preneoplastic and neoplastic 
squamous cell lesions of cervix, were analyzed during the period of June 2014 
to August 2015 
Inclusion criteria   
Tissue blocks of patients who are diagnosed as CIN (Cervical 
Intraepithelial neoplasia) I, II, III and squamous cell carcinoma of cervixon 
histopathological examination were included in this study.  
Exclusion criteria: 
Tissue blocks of squamous cell carcinoma patients who underwent 
Radiotherapy or Chemotherapy were excluded in this study. 
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Methodology and Technique Used: 
Materials needed: 
x Hematoxylin & Eosin stain 
x p16 INK4a  immunohistochemical  marker kit 
x Formalin fixed & paraffin embedded blocks which were reported as 
CIN I, II, III and Squamous Cell Carcinoma of Cervix 
Methods : 
x All blocks and slides of 60 patients in whom Cervix biopsy was 
reported as CIN I, II, III and Squamous Cell Carcinoma of Cervix as 
per standard protocol were taken for study. 
x Immunohistochemistry was performed on the 60 study sections. 
x 4-micrometer thin sections were cut & placed on charged slides and 
incubated at 60 – 70 degree Celsius for 1 hour. 
x Sections were deparaffinized  in xylene  for 15 minutes x 2 changes and 
rehydrated through graded alcohols as follows:- 
¾ Absolute alcohol – Two changes for 5 minutes each. 
¾ 90% alcohol         - for 5 minutes 
¾ 70% alcohol         - for 5 minutes 
x Then sections were washed in distilled water two changes  for 2 
minutes each. 
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x Antigen retrieval was carried out at 150 degree Celsius in citrate buffer,         
(pH = 9) for 15 min and washed in Tris Buffer Solution buffer solution 
for 20 minutes. 
x The slides were cooled to room temperature and washed in distilled 
water for 2 changes 5 minutes each. 
x Then washed in Tris Buffer Solution for 2 minutes. 
x By adding 1% hydrogen peroxide on the sections and kept for 5 
minutes the endogenous peroxidase activity was blocked. 
x The slide was washed in buffer solution for 2 minutes each. 
x Primary antibody (p16INK4a– clone G175 – 405 – Mouse monoclonal 
antibody) was added and kept for 30 minutes at room temperature then 
washed in  buffer solution for two minutes, two times each. 
x Secondary antibody (Polyexcel Target binder reagent) was applied and 
kept for 15 minutes then washed in two changes of buffer 2 minutes 
each , followed by incubation with Horse radish peroxidase  for 15 
minutes .  
x Colour was developed by incubating the sections with diamino 
benzidene for 5 minutes then washed in distilled water & sections were 
counter stained with haematoxylin for 2 seconds.  
x The slides were washed in running tap water for 3 minutes. The slides 
were air dried, cleared with xylene and mounted with DPX. 
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x For positive control – Histological section of Squamous Cell 
Carcinoma Cervix with known P16 positivity was included in each 
batch of staining. 
x For negative control – Phosphate buffer solution was used instead of 
primary antibody. 
x  p16, immunostained sections were reviewed. Chestnut brown colour in 
the nucleus and/or cytoplasm was considered as immuno positivity.  
x Grading was performed for each case by counting  the number of 
positive cells in different epithelial clusters as Grade 1( 1 – 5 % ), 
Grade2(5–25%) and Grade 3(>25%,), based on the number of positive 
cells. 
DATA COLLECTION:-  
All the 60 histopathological slides were reviewed and the diagnosis was 
categorized as below:- 
¾ Cervical Intraepithelial neoplasia - I  ( CIN-I ) 
¾ Cervical Intraepithelial neoplasia -II ( CIN-II ) 
¾ Cervical Intraepithelial neoplasia - III ( CIN-III ) 
¾ Early invasive squamous cell carcinoma of cervix. 
¾ Large cell keratinizing Squamous cell carcinoma of cervix. 
¾ Large cell non keratinizing Squamous cell carcinoma of cervix. 
¾ Small cell non keratinizing Squamous cell carcinoma of cervix. 
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Interpretation of p16INK4a   staining 
For all the above 60 cases p16 expression was expressed. Two 
parameters were evaluated in p16 expression. 
1. Percentage of p16 positive cells 
2. Reaction intensity of p16 immunostaining 
The percentage of p16ink4a   positivity was graded by determining the 
percentage of p16ink4a imunoreactive cells that is percentage of cells with brown 
nuclear and/ or cytoplasmic reactivity. The grading for p16 expression was 
graded as below. 
Negative 
x When no cells stained     
x Weak Cytoplasmic staining  
Positive 
x Grade 1 :-positive cells >0 – 5% 
x Grade 2 :-positive cells >5 – 25% 
x Grade 3 :-positive cells >25% 
P16 intensity of reaction was scored as:- 
x Negative 
x Weak 
x Moderate  
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x Strong 
Statistical analysis: 
 Data obtained was coded and entered into Microsoft excel spread sheet 
(Annexure II). The data was analyzed by using SPSS version 16. Continuous 
data was expressed as mean and median. Correlation between 
histopathological results and immunohistochemistry results were calculated by 
chi-square test. 
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OBSERVATION AND RESULTS 
 Our present cross sectional study was a prospective study conducted in 
the Department of Pathology during the period of June 2014 to August 2015. 
Ethical clearance for the study was obtained from the Ethics Committee of 
Chengalpattu  Medical college, Chengalpattu. 
A total sample of 60 cases, including CIN I, CIN II, CIN III, and  
squamous cell carcinoma of cervix were analysed during the period of 
June2014  to August 2015.Data obtained were coded and entered into 
Microsoft excel spread sheet and analysed as below. Results are represented in 
the form of pie diagrams and bar charts.  
TABLE 8: AGE WISE DISTRIBUTION OF CERVICAL SQUAMOUS 
LESIONS  
AGE GROUP 
CIN I 
n = 25 
CIN II 
n = 5 
CIN III 
n = 4 
SCC 
n = 26 
< 30 Years 5 (20%) 0 0 0 
31-40 7 (28%) 1 (20%) 1 (25%) 2 (7.7%) 
41-50 8 (32%) 1 (20%) 1 (25%) 8 (30.8%) 
51-60 3 (12%) 2 (40%) 1 (25%) 11 (42.3%) 
>60 2 (8%) 1 (20%) 1 (25%) 5 (19.2%) 
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Figure 13: Age Wise Distribution of Cervical Squamous Lesions 
 
 From the above table (8) & figure (13)  it is evident that, low grade 
preneoplastic lesions (CIN I) are seen most commonly in 41 – 50 years of age, 
high grade lesions (CIN II, III) and squamous cell carcinoma are most 
commonly seen in 51 – 60 years of age. The age range of the 60 patients in the 
present study was 27 years  to 83 years with a median age 48.5years. Mean 
age of all patients included in this study was 49.85+12.6. Mean age of CIN I 
was 42.40years, CIN II was 54.80 years ,CIN III57.25 years and SCC was 
54.92 years. 
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Table 9: Incidence of Preneoplastic and Neoplastic Lesions of cervix in 
relation to parity 
PARITY 
CIN I 
n = 25 
CIN II 
n = 5 
CIN III 
n = 4 
SCC 
n = 26 
Nulliparity 2 (8%) 1 (20%) 0 0 
1 -2 20 (80%) 2 (40%) 1 (25%) 13 (50%) 
3-4 3 (12%) 2 (40%) 3 (75%) 13 (50%) 
Chi sq=14.76,P value=0.02 
 
Figure 14:  Incidence of Preneoplastic and Neoplastic Lesions of Cervix in 
Relation to Parity 
 
Table and figure mentioned above shows that, in our study  low grade 
squamous intraepithelial lesions (CIN I) were more common in  para (1 – 2) 
women, high  grade lesions  (CIN II, CIN III) were more common in para (3 – 
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4)  women.In our study, regarding SCC there is no difference in the incidence 
of SCC in women with para 1- 2 and para 3- 4. 
Table 10: Incidence of Various Symptoms in Cervical Squamous Lesions 
HPE Diagnosis 
SYMPTOMS 
White Discharge Post Coital Bleeding 
Postmenousal 
Bleeding Metrorhagia 
CIN (I, II, III) 29 (76.3%) 3 (25%) 0 5 (50%) 
SCC  9 (23.7%) 9 (75%) 15 (100%) 5 (50%) 
TOTAL 38 12 15 10 
Chi sq 18.12 11.03 26.15 3.27 
P value 0.001 0.01 0.0001 0.3 
 
 In our study it is noted that most of the patients presented with white 
discharge. The commonest presenting complaint was white discharge in 
patients with all grades of CIN and post-menopausal bleeding in patients with 
squamous cell carcinoma of cervix 
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Figure 15:  Incidence of Various Symptoms in Cervical Squamous 
Lesion. 
 
Table 11:  Correlation Between Visual Screening Methods and Biopsy 
Diagnosis 
HPE DIAGNOSIS VIA / VILI  POSITIVE 
CIN I   (n =25) 14 (58.3%) 
CIN II  (n = 5) 3 (12.5%) 
CIN III ( n = 4) 1 (4.2%) 
SCC    ( n = 26) 6 (25%) 
Total 24 
 
In the present series, out of 60cases VIA / VILI was done for 24 twenty 
four patients and found positive for all 24 patients. Of the twenty four cases, 
14 were diagnosed as CIN I , 3 cases were CIN II ,one was CIN III and 6 cases 
were diagnosed as squamous cell carcinoma of cervix. 
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Figure 16:  Correlation Between Visual Screening Methods And Biopsy 
Diagnosis  
 
Table 12:  Degree of Distribution of Cervical Squamous Intraepithelial 
Lesion in all Cervical  Biopsies. 
NATURE OF 
LESION  IN CERVIX 
DISTRIBUTION 
NUMBER 
OF CASES 
( n = 34) 
PERCENTAGE 
CIN I 25 73.5% 
CIN II 5 14.7% 
CIN III 4 11.8% 
 
 
 
58.30%
12.50%
4.2%
25%
VIA / VILI  POSITIVE
CIN I
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CIN III
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Figure17: Degree of Distribution of Cervical Squamous Intraepithelial 
Lesion in all Cervical biopsies. 
 
In the present study, among 34 cervical intra epithelial lesion , majority 
of them were CIN I accounting for 73.5%, followed by CIN II with 14.7% and 
the least being CIN III accounting for 11.8%. 
Table 13:  Distribution of Various Histological Subtypes of Squamous 
Cell Carcinoma of Cervix 
NATURE OF LESION  
IN CERVIX 
DISTRIBUTION 
NUMBER OF CASES 
n = 26 
PERCENTAGE 
 
Early Invasive SCC 
2 7.7% 
Large Cell Keratinizing 
SCC 6 23.1% 
Large Cell Non- 
Keratinizing SCC 16 61.5% 
Small Cell Non-
Keratinizing SCC 2 7.7% 
73.50%
14.70%
11.80%
CIN I
CIN II
CIN III
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 In our study it was noted that, among 26 squamous cell carcinoma 
cases, 16 cases were diagnosed as Large Cell Non- Keratinizing SCC, 6 cases 
were diagnosed as Large Cell Keratinizing SCC, 2 cases as Early Invasive 
SCC and 2 cases as Small Cell Non-Keratinizing SCC.  
Figure18: Distribution of Various Histological Subtypes of Squamous Cell 
Carcinoma of Cervix 
 
Table 14: Results of P16 Ink4a Immunostaining in Cervical Squamous 
Cell Lesions 
LESION P16 +ve Cases p16 negative cases 
CIN I 7/25 (28%) 18/25 (72)% 
CIN II 4/5 (80%) 1/5 (20%) 
CIN III 4/4 (100%) 0 
SCC 26/26 (100%) 0 
Total 41/60 (68.33%) 19/60 (31.67%) 
Chi sq = 33.01, p =0 .0001 
7.70%
23.10%
61.50%
7.70%
Early Invasive SCC
Large Cell Keratinizing SCC
Large Cell Non-
Keratinizing SCC
Small Cell Non-
Keratinizing SCC
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 Among CIN I group, majority of them (72%) were observed p16 
negative in contrast to CIN II , CIN III and SCC, in which most of the cases 
showed p16 positivity. On making comparison between  p16 expression 
versus different grades of CIN and SCC  it was found to be statistically 
significant ( P =0 .0001).  
Figure19:  Results of P16 Ink4a Immunostaining in Cervical   Squamous 
Cell Lesions 
 
Table 15:  Grading of P16 Ink4a Expression in Preneoplastic and 
Neoplastic Squamous Cell Lesions of Cervix 
LESION -Ve Grade 1 Grade 2 Grade 3 
CIN I 18/25 (72)% 3/25 (12%) 3/25 (12%) 1/25 (4%) 
CIN II 1/5 (20%) 0 1/5 (20%) 3/5 (60%) 
CIN III 0 0 0 4/4 (100%) 
SCC 0 0 1/26 (3.85%) 25/26 (96.15%) 
Chi sq = 50.26, p =0 .0001 
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80%
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CIN I CIN II CIN III SCC
28%
80%
100% 100%
72%
20%
P16 +ve Cases p16 negative cases
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 Above mentioned table showed that expression of p16INK4ais increased 
with increasing grades of CIN and also in squamous cell carcinoma. Majority 
of the CIN I cases(72%) werep16 negative.p16 expression in CIN II  was 80% 
and CIN III was 100%. 4% of CIN I case, 60% of the CIN II cases and 100% 
of the CIN III cases showed grade 3 staining. Most of the SCC (96.15%) 
showed grade 3 scoring for  p16 positivity except one case which showed 
grade 2 scoring. 
Figure 20 : Grading of P16Ink4a Expression in Preneoplastic and 
Neoplastic Squamous Cell Lesions of Cervix 
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Table  16: Correlation Between Histopathological Diagnosis and Reaction 
Intensity of P16 Staining: 
LESION -Ve Weak Moderate Strong 
CIN I 18/25 (72%) 0 6/25 (24%) 1/25 (4%) 
CIN II 1/5 (20%) 0 1/5 (20%) 3/5 (60%) 
CIN III 0 0 0 4/4 (100%) 
SCC 0 1/26(3.85%) 1/26 (3.85%) 24/26 (96%) 
Chi sq = 52.49, p = 0.0001 
In the present study it was noted that except CIN I , majority of the CIN 
II, III and SCC  showed strong reaction intensity for p16 immunostaining. 
Figure 21: Correlation Between Histopathological Diagnosis and Reaction 
Intensity of P16 Staining: 
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COLOUR PLATES 
 
Figure 22  : Cervical intraepithelial neoplasia I (CIN I) . H&E (100X) 
 
Figure23  : Cervical intraepithelial neoplasia I (CIN I) . Negative p16 IHC 
staining (100X) 
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Figure24 :Cervical intraepithelial neoplasia I (CIN I) . p16 IHC staining 
Grade 1 staining. (400X) 
 
Figure25  :Cervical intraepithelial neoplasia I (CIN I) . p16 IHC staining 
Grade 2 staining. (400X) 
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Figure26 :Cervical intraepithelial neoplasia II (CIN II) . H&E (100X) 
  
 
 
 
 
Figure27 : Cervical intraepithelial neoplasia II (CIN II) . p16 IHC 
staining Grade 2,3 staining. (400X) 
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Figure28 : Cervical intraepithelial neoplasia III (CIN III) . H&E (100X) 
 
 
Figure 29: Cervical intraepithelial lesion III (CIN III).P16 IHC 
immunostaining Grade 3 (100X) 
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Figure30 : Early invasive squamous cell carcinoma. H& E.(100X) 
 
 
Figure 31: Early invasive squamous cell carcinoma.P16 immunostaining 
shows grade 3 immunostaining (400X) 
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Figure 32 : Large cell keratinizing  squamous cell carcinoma. H& E. 
(100X) 
  
Figure 33: Large cell keratinizing squamous cell carcinoma.P16 
immunostaining shows grade2& 3 immunostaining(400X) 
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Figure 34: Large cell non keratinizing  squamous cell carcinoma. H& 
E.(100X) 
 
Figure 35: Large cell non keratinizing squamous cell carcinoma.P16 
immunostaining shows grade 3 immunostaining 
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Figure 36: Small cell non keratinizing  squamous cell carcinoma. H& 
E.(100X) 
 
Figure37: Small cell non keratinizing squamous cell carcinoma.P16 
immunostaining shows grade 3 immunostaining 
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Figure 38: p16 immunostaining showing weak reaction intensity 
 
Figure 39: p16 immunostaining showing moderate reaction intensity of 
p16 staining 
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Figure 40: p16 immunostaining showing strong reaction intensity of               
p16 staining. 
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DISCUSSION 
Cervical cancer is one of the leading causes of morbidity and mortality 
among women worldwide. Many studies revealed the association of human 
papilloma virus infection in both precancerous and invasive cervical cancer.97 
Most of the HPV infection are transient, if it persists the risk of developing 
preneoplastic lesions increases as well as the risk of developing cervical 
cancer.98 
       Among various types of cervical carcinoma, squamous cell carcinoma 
constitutes majority which is preceded by cervical intraepithelial lesion (CIN) 
and the later plays an important critical point in the natural history of cervical 
cancer. 
Pap smear screening and histopathological examination and 
interpretation of cervical biopsy specimen has markedly reduced the number 
of deaths due to cervical cancer, however they give little information 
regarding the association of HPV infection, risk of progression or regression 
and prognosis. Most of the low grade intraepithelial lesion and some of the 
high grade lesion regress spontaneously overtime without treatment.99 So 
overtreatment of patients who will not benefit from treatment or under 
treatment of patients who have the risk of progression, underscores the 
importance of detection of HPV in those lesions. Furthermore absence of 
detection of HPV in cervical cancer cells is associated with poor prognosis.100 
Hence HPV detection in those lesions play a pivitol role to differentiate HPV 
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positive from HPV negative SCC by which we can assess the prognosis of the 
patient.  
P16 has recently emerged as a surrogate marker of HPV, used both in 
cytology and histology sections, it significantly reduce the interobserver 
variability when diagnosing cervical intraepithelial lesion, furthermore it’s 
over expression appears to correlate with degree of cervical intraepithelial 
neoplasia.101 
P16 over expression in low grade cervical intraepithelial lesion have a 
higher risk of persistence and progression to high grade lesion.102In future we 
can plan HPV vaccine trials in areas with HPV high prevalence.  So 
identifying the association of HPV in preneoplastic and neoplastic lesions has 
significant implication in diagnostic, follow-up , prognostic and preventive 
aspects of cervical cancer. 
In the present study total number of cervical biopsy sampled were 
60.The overall age range of the 60 patients was 27 – 83 years with mean of 
49.85years and median age of 48.5 years. The observations by Kim et al and 
our study are coinciding. 
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TABLE 17: AGE COMPARISON 
AGE 
PARAMETERS 
Kim et al 
2015103 
Benevolo 
et al 
2006104 
Poste et al 
2015105 
Present 
study 
Age range 24 –80 yrs 18 -82 yrs 29 – 82 yrs 27 -83 yrs 
Median age 47 yrs 41 yrs - 48.5 yrs 
Mean age -  41 yrs - 49.85 yrs 
Common age 
range of CIN 
-  - 41 – 50 yrs 41 – 50 yrs 
Common age 
range of SCC 
-  - 51- 60 yrs 51- 60 yrs 
 
Majority of low grade lesions were seen in 41 – 50 years and SCC were 
seen in  51 – 60 years age group ,which is similar to study done by poste et al. 
In our study patients with mean age of high grade CIN(mean 56.02),and SCC 
(mean 54.92) were older compared to CIN I (mean 42.40). 
Table18: Comparison of Incidence of Parity Among Preneoplastic and 
Neoplastic Lesions of Cervix 
Parity 
Urmila Banik et al106 
(2011) 
n = 139 
Present study 
 n = 60 
0  - 2 24  (17.27%) 39 (65%) 
3  - 4 52  (37.41%) 21 (35%) 
>5 63  (43.32%) -- 
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 Majority of the patients in the present study were primi para and second 
para. Many studies have shown that multiparity is one of the risk factor 
associated with development of carcinoma. In Urmila et al study majority of 
the patient was parity of > 5. In the present study, no significant correlation 
exists between multiparity and SCC. 
Table 19: Comparison of incidence of various symptoms in CIN & SCC 
Symptoms 
Kamna Gupta etal 
2013 
 
Present Study 
 
Poste 
etal 
(CIN) 
2015 
(n=51) 
CIN 
(n=87) 
SCC 
(n=11) 
CIN(n=34) SCC(n=26) 
White 
discharge 
42 cases 
(48.27 % ) 
0% 
29 cases 
(85.29%) 
9 cases 
(34.62%) 
17  
cases 
33.33% 
Post coital 
bleeding 
23 cases 
(26.43%) 
4 cases 
(36.36%) 
3 cases 
(8.82%) 
9 cases 
(34.62%) 
10 cases 
19.6% 
Post 
menopausal 
bleeding 
6 cases 
(6.90%) 
5 cases 
(45.45%) 
- 
15 cases 
(57.69%) 
1 case 
1.96% 
Metrorrhagia 
15 cases 
(17.24%) 
2 cases 
(18.18%) 
5 cases 
(14.7%) 
10 cases 
(38.46%) 
19 cases 
37.25% 
 
 From the above table it is seen that most common complaint in patients 
with CIN was white discharge and in patients with SCC was post menopausal 
bleeding. Our finding is concordant with Kamna gupta et al.107 But in poste et 
al the predominant complaint of CIN patients was metrorrhagia. 
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           In our study VIA / VILI was done for 24 cases and it was found 
positive in all 24 cases (100%). Out of 24 cases, 14 cases(58.3%) were 
diagnosed as CIN I, 3 cases(12.5%) were diagnosed as CIN II(12.5%) , one 
case(4.2%) as CIN III and 6 cases(25%) were diagnosed as SCC. A study by 
Ghosh et al in 2010 observed that among 34 VIA / VILI positive cases, 
11cases (32.35%) had CIN I, 4 cases (11.4%) had CIN II, 1case (2.94%) had 
CIN III and 1case (2.94%) had invasive cancer. In low resource countries pap 
smear screening can be replaced or combined with VIA /VILI to detect 
precancerous and cancerous lesions. 
Table 20: Comparison of Incidence of CIN with other Studies 
 
CIN 
GRADE 
Sophia S 
Wang et al108 
(2014) 
(no of cases) 
(n = 292) 
Tan et al109 
(2010) 
(no of cases) 
(n = 129) 
Nam et al110 
(2008) 
(n = 24) 
Present 
study 
( n = 60) 
CIN I 75 cases 60 cases 12cases 25 cases 
CIN II 19 cases 21 cases 6cases 5 cases 
CIN III 19 cases 
48 cases 
 
6cases 
4 cases 
 
 
     In the present study of 60 cases , CIN I constituted the major group 
accounting for about 73.5% followed by CIN II, III , accounting 14.7% , 
11.8% respectively. The lesion with highest incidence was CIN I in our study 
and is similar to the incidence quoted by Wang et al, Tan et al and Nam et al. 
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Table 21:  Comparison of Distribution of Various Histological Subtypes of 
Squamous Cell Carcinoma 
SUPTYPE 
OF SCC 
 
Purnima 
poste et al 
(2015) 
( n = 157) 
Vatsala 
misra et al 
(1997)111 
( n = 98) 
 
Adisorn 
Jedpiyawongse 
et al (2008)112 
( n = 29) 
Present 
study 
No of cases 
(%) 
( n = 26) 
Early 
invasive SCC - - 13(25%) 2(7.7%) 
Large cell 
keratinizing 
SCC 
48(30.5%) 18(18.37%) 1(1.8%) 6(23.1%) 
Large cell 
keratinizing 
SCC 
103(65.60%) 68(69.39%) 14(26.4%) 16(61.5%) 
Small cellnon 
keratinizing 
SCC 
6(3.82%) 4(4.08%) 1(1.8%) 2(7.7%) 
 
Among SCC, majority of them were of large cell non keratinizing 
subtype. The incidence of this is similar to the incidence quoted by other 
authors. Non keratinizing tumors of cervix had better prognosis when 
radiotherapy is used, but there was no significant difference in the prognosis 
when the treatment is surgical. 
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Table 22:   Comparison of P16 Positivity in CIN & SCC with Other 
Studies 
Sl. 
no. Authors CIN1 CIN2 CIN3 SCC 
1. Klaes et al 2002 15/17 (88%) 10/10 (100%) 43/43 (100%) 46/46 (100%) 
2. Benovolo 2006 17/54 (31%) 9/10 (90%) 11/11 (100%) 8/8 (100%) 
3. Kim et al 2015 22/31 (70.9%) 21/25 (84%) 41/41 (100%) 35/35 (100%) 
4. Tan et al 2010 16/60 (26.7%) 9/21 (42.9%) 46/48 (95.9%) 71/72 (98.6%) 
5. Present Study 7/25 (28%) 4/5 (80%) 4/4 (100%) 26/26 (100%) 
 
In SCC, 100% p16 positivity was noted in our and other studies. In CIN 
III p16 positivity (100%) was correlate with other studies. In CIN II 
p16positivity (80%) was correlated with other studies except Tan et al. In CIN 
I , the positivity(28%) correlated with Benovolo et al and Tan et al. Among 
preneoplastic lesions, totally 44.12% of cases including CIN I, II, III showed 
p16 positivity. 
In the present study, we observed p16 negativity in majority of the CIN 
I samples (72%). Sano T et al indicated that low risk HPV E7 oncoprotein 
have no effect on p16 expression, because its affinity is 10 times lower than 
that high risk HPV E7 oncoprotein.113 Tan et al in 2010 stated that low grade 
lesion with p16 negativity may be due to infection with low risk HPV or due 
to subclinical infection. 
In the present study all the CIN III and SCC cases were p16 positive. 
The results of expression of p16 in all grades of CIN and SCC was statistically 
significant (p =0.0001) and is concordant with the above literatures. 
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A study by volgareva et al in 2004, observed that some of the 
preneoplastic and neoplastic lesions of cervix do not express p16. They 
suggested that due to lack of p16 positivity we should not exclude a patient 
from risk group. They concluded that absence of p16 expression may be due to 
p16 mutation, deletion or hypermethylation.114 
Table 23 : Comparing Grade of P16 Expression in Squamous Cell Lesions 
of Cervix. 
Study P16 Expression grading Lesion Negative Grade 1 Grade 2 Grade 3 
 
 
 
Kleas et al 
(2001)115 
 
 N % n % n % n % 
CIN I 
n=47 
 
7 
 
14% 
 
2 
 
4% 
 
10 
 
21% 
 
29 
 
61% 
CINII 
n=32 
 
- 
 
0% 
 
- 
 
0% 
 
- 
 
0% 
 
32 
 
100% 
CINIII 
n=60 
 
- 
 
0% 
 
- 
 
0% 
 
- 
 
0% 
 
60 
 
100% 
SCC 
n=60 
 
2 
 
3% 
 
- 
 
   0% 
 
- 
 
0% 
 
58 
 
97% 
 
 
 
Supriya  
Srivastava 
et al 
(2010)116 
CINI 
n=10 
 
2 
 
20% 
 
   - 
 
  0% 
 
8 
 
80% 
 
- 
 
0% 
CINII 
n=5 
 
- 
 
0% 
 
- 
 
0% 
 
3 
 
60% 
 
2 
 
40% 
CINIII 
n=3 
 
- 
 
0% 
 
- 
 
0% 
 
- 
 
0% 
 
3 
 
100% 
SCC 
n=15 
 
- 
 
0% 
 
- 
 
0% 
 
- 
 
0% 
 
15 
 
100% 
 
 
 
Present  
study 
CINI 
n=25 
 
18 
 
72% 
 
3 
 
12% 
 
3 
 
12% 
 
1 
 
4% 
CINII 
n=5 
 
1 
 
20% 
 
- 
 
0% 
 
1 
 
20% 
 
3 
 
60% 
CINIII 
n=4 
 
- 
 
0% 
 
- 
 
0% 
 
- 
 
0% 
 
4 
 
100% 
SCC 
n=26 
 
- 
 
0% 
 
- 
 
0% 
 
1 
 
3.85% 
 
25 
 
96.15% 
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In the present study it was noted that there was a significant increase in 
the grade of p16 expression, when we moved from low grade cervical 
intraepithelial lesion to squamous cell carcinoma and the correlation was 
found to be statistically significant (p value = 0.0001%).In SCC, 96.15% of 
cases showed grade 3 expression. 
Kleas et al in 2001 correlated the p16 expression in cervical lesions to 
the HPV status of the sample by using PCR. They grade the p16 expression as 
negative , sporadic ,focal and diffuse. All CIN I lesions with low risk HPV 
showed no diffuse staining, but  CIN I with high risk HPV displayed diffuse 
p16 expression . Finally they concluded that p16 may be useful to identify the 
dysplastic cervical cells in both cytology and histopathology. In the present 
series one CIN I case showed grade 3 expression of p16 which need greater 
attention, because of increased risk of persistence and progression to high 
grade lesion. So p16 could be used asa suitable marker of HPV infection to 
predict the outcome of CIN lesions. 
Ishikawa et al analysed the p16 expression and HPV typing in cervical 
lesions and found that p16 overexpression in CIN I was more common in 
patients with HPV 16 and 52.117 
A study by supriya srivastava( 2010) et al analyzed the expression of 
both p16 and MIB1 in cervical lesions and normal cervical epithelium. They 
found the expression of both in all cases of CIN I, II, III and cancer cervix 
except in normal cervical epithelium. In their study they grade the number of 
p16 positive cells as grade 0(0% positive cells) ,1(1 – 10%positive cells) ,2(10 
– 50% positive cells) and 3 (>50%p16 positive cells). 
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A study by Riou G et al (1990) examined 106 cases of early invasive 
squamous cell carcinoma of cervix with HPV sequencing by PCR and 
southern hybridization and concluded that there was 2.6 times higher chance 
of relapse and 4.5 times higher chance of distant metastasis in HPV negative 
patients when compared to HPV positive patients. So detection of  HPV in 
those lesions indicate better prognosis. 
Table 24: Correlation between p16 Reaction Intensity and Histological 
Diagnosis with Other Studies 
Study 
HPE 
Diagnosis 
P16 reaction intensity 
Negative Weak Moderate Strong 
Izadi Mood 
et al 2012 
Low grade 
CIN 
(n = 11) 
2 (18.2 %) - 9 (81.8%) - 
High grade 
CIN(n  = 11) 
1 (9.09 %) - 2 (18%) 8 (72.7%) 
SCC(n = 20) 2 (10%) 1 (5%) 2 (10%) 15 (75%) 
Present 
Study 
Low grade 
CIN 
(n = 25) 
18 (72%) - 6(24%) 1(4%) 
High 
gradeCIN 
(n = 9) 
1 
(11.11%) 
- 1(11.11%) 7(77.77 %) 
SCC 
(n =26) 
- 1(3.85%) 1(3.85%) 24(96.15%) 
           
 Izadi mood et al in 2012 observed a direct relationship between 
reaction intensity and lesion severity. They concluded that p16 reaction 
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intensity was superior than any other analyzed parameter and they found it 
being the best indicator of p16 expression.119 
In the present study majority of the low grade CIN were negative for 
p16 reaction intensity, but all other findings were concordant with the above 
literature. There was a statistically significant relationship between 
histopathological diagnosis and p16 reaction intensity in our study (p < 
0.0001).  
 
 
 
 
 
 
 
 
 
 
 
 
 88 
 
SUMMARY 
          Cervical cancer is one of the most common malignancy among women 
worldwide.HPV plays an important role in the development of premalignant 
and malignant tumors of cervix. Routine screening methods may not detect 
HPV in those lesions. Hence the present study was undertaken to know the 
association of HPV in those lesions, which is very useful to predict the 
progression of the disease. In our study all the 60 cases were analyzed with  
p16 INK4A marker , which is a  surrogate marker of HPV. 
        The overall age range of patients in this study was between 27 years to 
83 years, with a mean of 49.85 years and median of 48.5 years. Majority of the 
patients with low grade CIN belonged to the age group of 41 – 50 years, and 
SCC belonged to 51 – 60 years. 
       Most of the patients in this case series were para 1-2.High grade lesions 
were seen in para 3-4 patients. 
White discharge and Metrorrhagia were the most common symptoms of 
patients with CIN, it was seen in 76.3% of patients, whereas post menopausal 
bleeding was the most common symptom of squamous cell carcinoma 
patients.VIA/ VILI was found positive in 100% of the tested patients 
        In this study OUT OF 60 cases CIN constituted 56% and SCC 
constituted 44%.Among all CIN cases, CIN I constituted majority of the cases. 
Large cell non keratinizing SCC was the commonest subtype of SCC 
comprising 61.5%. 
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Overall in 60 cases, 68.33% of patients sample showed p16 expression, 
out of this 28% of CIN I, 80% of CIN II and all CIN III and all SCC cases 
showed p16 expression. One CIN I case and majority of the CIN 2, 3 and SCC 
cases scored grade 3 p16 staining. 
In the current study 4% of the CIN I, 60% of CIN II, 100% of CIN III 
and 96.15% of SCC cases showed strong reaction intensity for p16 staining. 
In our study we found statistically significant relationship between p16 
expression, reaction intensity and histopathological diagnosis. 
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CONCLUSION 
The present cross sectional study titled “Analysis of 
Immunohistochemical Expression of p16INK4a in preneoplastic and 
neoplastic squamous cell lesions of cervix” was conducted in the department 
of pathology from June 2014 to August 2015. 
Following conclusions were arrived from this study:- 
¾ Low grade lesions were seen in younger age group(41 – 50 years) 
compared to high grade lesions which were seen in older age group (51 
– 60years). 
¾ Among preneoplastic lesions, low grade cervical intraepithelial lesions 
were found in low parity women and high grade lesions were seen in 
high parity women. In invasive squamous cell carcinoma, there is no 
significant relation with high parity. 
¾ VIA / VILI showed 100% positivity for all the tested cases. 
¾ As nearly 70% of all preneoplastic and neoplastic lesions of cervix 
showed p16 over expression in our region, further studies can be 
undertaken to evaluate the prevalence of high risk HPV in general 
population, which can help us to take necessary steps to minimize and 
prevent the infection through health education and HPV vaccination.  
¾ Low grade cervical intraepithelial lesions showed less reaction intensity 
and less grade of staining. P16 expression was progressively increased 
with increasing grades of cervical neoplasm. So p16 may be useful as 
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an adjunct in histological sections to detect HPV in those lesions which 
can help us to predict the progression of disease. High grade cervical 
intraepithelial lesions and squamous cell carcinoma cases showed 
strong reaction intensity and higher grade of staining. If we detect the 
association of HPV in SCC, we can predict the prognosis of the patient. 
¾ The limitation of our study was we did not attempt for HPV DNA 
detection studies to validate the utility of p16 for detection of HPV in 
cervical neoplasm. 
 
 
. 
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ANNEXURE I 
PROFORMA 
Demographic details:- 
1. Name     :        Date: 
2. Age         : 
3. 0P / IP NO   : 
4. Parity           : 
5. Symptoms   : 
Clinical Diagnosis:- 
VIA / VILI :-  Positive / Negative / Not done 
Histopathological confirmation and grading of H&E stained section 
¾ Cervical Intraepithelial neoplasia - I  ( CIN-I ) 
¾ Cervical Intraepithelial neoplasia -II ( CIN-II ) 
¾ Cervical Intraepithelial neoplasia - III ( CIN-III ) 
¾ Early invasive squamous cell carcinoma of cervix. 
¾ Large cell keratinizing Squamous cell carcinoma of cervix. 
¾ Large cell non keratinizing Squamous cell carcinoma of cervix. 
¾ Small cell  non keratinizing Squamous cell carcinoma of cervix. 
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p16INK4a Expression 
Negative 
Positive 
x Grade 1  
x Grade 2  
x Grade 3  
P16 intensity of reaction :- 
x Negative 
x Weak 
x Moderate  
x Strong 
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MASTER CHART 
Sl. 
No Gynaec No: Age Specimen Type VIA / VILI HPE diagnosis Parity Symptoms p16 expression p16 Intensity 
1 Gy1591/14 30 Cervix - Biopsy Positive CIN I P1 WD - Ve   - Ve 
2 Gy1596/14 60 Cervix - Biopsy Positive CIN II P2 MET,PCB 3 S 
3 Gy1598/14 35 Cervix - Biopsy Positive CIN II NP WD 2 M 
4 Gy1599/14 38 Cervix - Biopsy Positive CIN III P2 WD 3 S 
5 Gy1755/14 50 Cervix - Biopsy ND CIN III P3 WD,PCB 3 S 
6 Gy1837 / 14 30 Cervix - Biopsy Positive CIN I P2 WD 1 M 
7 Gy1870/14 55 Cervix - Biopsy ND CIN I P2 WD 2 M 
8 Gy1911/14 70 Cervix - Biopsy ND  SCC  - large cell  keratinizing type P4 PMB 2 M 
9 Gy1958/14 48 Cervix - Biopsy ND  SCC -large cell non keratinising type P2 MET , PCB 3 S 
10 Gy2070 55 Cervix - Biopsy Positive SCC  - large cell  keratinizing type P2 PMB 3 S 
11 Gy2112 38 Cervix - Biopsy ND  SCC  - large cell  keratinizing type P1 PCB, MET 3 W 
12 Gy2296 60 Cervix - Biopsy ND  SCC  - large cell  non keratinizing type P4 PMB 3 S 
13 Gy2315 34 Cervix - Biopsy Positive CIN I P2 WD  - Ve   - Ve 
14 Gy2433 48 Cervix - Biopsy ND CIN I P2 MET - Ve   - Ve 
15 Gy2442 35 Cervix - Biopsy ND CIN I P1 WD  - Ve   - Ve 
16 Gy2483 45 Cervix - Biopsy Positive CIN I P1 WD 2 M 
17 Gy2500 52 Cervix - Biopsy ND CIN I P2 WD   - Ve   - Ve 
18 Gy2503 27 Cervix - Biopsy ND CIN I NP WD   - Ve   - Ve 
19 Gy2631 56 Cervix - Biopsy Positive  SCC  - large cell  non keratinizing typE P2 PMB  3 S 
20 Gy2984 30 Cervix - Biopsy Positive CIN I P1 MET 3 S 
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Sl. 
No Gynaec No: Age Specimen Type VIA / VILI HPE diagnosis Parity Symptoms p16 expression p16 Intensity 
21 Gy3045 36 Cervix - Biopsy Positive CIN I P2 WD  - Ve   - Ve 
22 Gy3046 45 Cervix - Biopsy ND  SCC  - large cell  non keratinizing type P3 PCB , WD 3 S 
23 Gy3061 57 Cervix - Biopsy ND CIN I P3 WD  - Ve   - Ve 
24 Gy3062 33 Cervix - Biopsy ND CIN I P1 WD  - Ve   - Ve 
25 Gy3077 43 Cervix - Biopsy ND CIN I P2 WD - Ve   - Ve 
26 Gy3242 70 Cervix - Biopsy ND CIN II P3 MET 3 S 
27 Gy3281 47 Cervix - Biopsy ND  SCC  - large cell  keratinizing type P2 PCB,WD 3 S 
28 Gy 3250 45 Cervix - Biopsy ND CIN I P2 WD  - Ve   - Ve 
29 Gy3306 42 Cervix - Biopsy ND  SCC  - large cell  non keratinizing type P2 PCB, MET 3 S 
30 Gy5 / 15 48 Cervix - Biopsy Positive CIN I P1 WD 1 M 
31 Gy21/15 35 Cervix - Biopsy Positive CIN I P3 WD   - Ve   - Ve 
32 Gy64/15 50 Cervix - Biopsy ND SCC  - large cell  non keratinizing type P3 MET, WD 3 S 
33 Gy77/15 60 Cervix - Biopsy ND  SCC  - large cell  non keratinizing type P2 PMB 3 S 
34 Gy111/15 58 Cervix - Biopsy ND CIN III P3 WD 3 S 
35 Gy206/15 65 Cervix - Biopsy Positive CIN-I P3 WD   - Ve   - Ve 
36 Gy208/15 65 Cervix - Biopsy Positive  SCC - large cell  non keratinizing type P3 PMB 3 S 
37 Gy219/15 49 Cervix - Biopsy Positive CIN II P3 WD,PCB   - Ve   - Ve 
38 Gy336/15  38 Cervix - Biopsy ND CIN-I P1 WD   - Ve   - Ve 
39 Gy338/15 60 Cervix - Biopsy ND  SCC -Early invasive type P3 WD 3 S 
40 Gy343/15 60 Cervix - Biopsy ND  SCC  - large cell  non keratinizing type P2 WD,PMB 3 S 
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Sl. 
No Gynaec No: Age Specimen Type VIA / VILI HPE diagnosis Parity Symptoms p16 expression p16 Intensity 
41 Gy347/15 30 Cervix - Biopsy Positive CIN-1 P1 WD   - Ve   - Ve 
42 Gy362/15 47 Cervix - Biopsy ND  SCC  - large cell  non keratinizing type P2 MET,PCB 3 S 
43 Gy530/15 60 Cervix - Biopsy ND  SCC  - large cell  non keratinizing type P3 PMB 3 S 
44 Gy632/15 83 Cervix-Biopsy ND CIN-III P3 WD 3 S 
45 Gy665/15 65 Cervix-Biopsy Positive CIN I P1 WD 2 M 
46 Gy714/15 60 Cervix-Biopsy ND  SCC -Early invasive type P2 PMB,WD 3 S 
47 Gy722/15 47 Cervix-Biopsy ND  SCC - small cell non keratinizing type  P2 PCB,US 3 S 
48 Gy888/15 60 Cervix-Biopsy Positive  SCC - large cell  non keratinizing type P4 PMB 3 S 
49 Gy928/15 65 Cervix-Biopsy ND  SCC - small cell non keratinizing type P2 PMB 3 S 
50 Gy982/15 65 Cervix-Biopsy ND  SCC  - large cell  non keratinizing type P3 PMB 3 S 
51 Gy1024/15 44 Cervix-Biopsy ND CIN-I P2 WD 1 M 
52 Gy1171/15 45 Cervix-Biopsy Positive CIN I P2 WD  - Ve   - Ve 
53 Gy1193/15 40 Cervix-Biopsy Positive CIN-I NP MET  - Ve   - Ve 
54 Gy1194/15 50 Cervix-Biopsy Positive CIN-I P2 WD - Ve   - Ve 
55 Gy1226/15 60 Cervix-Biopsy Positive SCC  - large cell  non keratinizing type P2 PMB 3 S 
56 Gy1312/15 35 Cervix-Biopsy ND  SCC  - large cell  keratinizing type P1 WD,PCB 3 S 
57 Gy1413/15 73 Cervix-Biopsy ND  SCC  - large cell  keratinizing type P3 PMB 3 S 
58 Gy1414/15 45 Cervix-Biopsy Positive  SCC  - large cell  non keratinizing type P2 PCB,WD 3 S 
59 Gy1458/15 60 Cervix-Biopsy ND CIN II P2 WD 3 S 
60 Gy1508/15 55 Cervix-Biopsy ND  SCC  - large cell  non keratinizing type P3 WD,PMB 3 S 
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ABBREVIATIONS FOR MASTER CHART 
VIA/VILI :  Visual inspection with acetic acid / Lugol’s Iodine   
CIN I  : Cervical intraepithelial neoplasia I 
CIN II  : Cervical intraepithelial neoplasia II 
CIN III : Cervical intraepithelial neoplasia III 
SCC  :  Squamous cell carcinoma 
ND  :  Not done( VIA/ VILI) 
 P1,2,3,4  :  Para 1,2,3,4 
NP  :  Nulliparity 
WD   :  White discharge                  
 MET  :  Metrorrhagia 
PCB  : Post coital bleeding 
PMB   : Post menopausal bleeding 
P16 expression 
-ve   :  Negative 
1 , 2 , 3 :  Grade 1 ,2 , 3 (p16 expression) 
 
P16  reaction intensity 
W   : Weak 
M   : Moderate   
S  :  Strong                                             
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ANNEXURE - III 
GLOSSARY 
LSIL    : Low grade squamous intraepithelial lesion 
HISL  : High grade squamous intraepithelial lesion 
CIN I  : Cervical intraepithelial neoplasia I 
CIN II  : Cervical intraepithelial neoplasia II 
CIN III : Cervical intraepithelial neoplasia III 
SCC  : Squamous cell carcinoma 
HPV  : Human papilloma virus 
RB  :  Retinoblastoma tumor suppressor gene 
PRb  : Retinoblastoma tumor suppressor gene product 
p16  : p16INK4a  
SCJ  :  Squamocolumnar junction  
ER  : Early region 
LR  : Late region  
URR   :  Upstream regulatory region 
CDK  : Cyclin dependant kinase 
PCR  :  Polymerase chain reaction 
ISH   : Insitu Hybridisation 
IHC   :  Immuno histochemistry 
MiRNA : microRNA 
VIA / VILI :  Visual inspection with acetic acid / Lugol’s Iodine 
